MedPath

PPIO-006 Primary Tumor Resection for IVa NSCLC

Completed
Conditions
Non-small-cell Lung Cancer (NSCLC)
Interventions
Procedure: Primary tumor resection or not
Registration Number
NCT06232967
Lead Sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Brief Summary

The goal of this mutli-center observational study is toinvestigate the impact of primary tumor resection (PTR) on the long-term survival of patients with non-small-cell lung cancer (NSCLC) and dry pleural dissemination (DPD). The main question it aims to answer is: whether primary tumor resection improve long-term survival of NSCLC patients with dry pleural dissemination.

Detailed Description

Non-small-cell lung cancer (NSCLC) patients with dry pleural dissemination have poor survival rates and are generally contraindicated for surgery. Previous single-center retrospective studies have suggested that these patients may benefit from primary tumor resection (PTR). However, the evidence supporting PTR is still limited, especially in the era of targeted therapy. This study aimed to investigate the impact of PTR on the long-term survival of patients with NSCLC and DPD.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
223
Inclusion Criteria

(1) pathologically confirmed primary NSCLC with malignant pleural dissemination, (2) no preoperative treatment, (3) age 80 years or younger, (4) clinicopathologic data and follow-up results were complete.

Exclusion Criteria

(1) pleural effusion, contralateral lung metastasis or distant metastasis revealed preoperatively, and (2) with a history of other malignant disease.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Primary tumor resection (PTR group)Primary tumor resection or notincludes wedge resection, segmentectomy, or lobectomy.
Primary Outcome Measures
NameTimeMethod
Disease-specific survival (DSS)Up to 8 years

The duration from the day of surgery to the the last follow-up visit or to death specifically caused by NSCLC.

Secondary Outcome Measures
NameTimeMethod
Progression-free survival (PFS)Up to 8 years

The duration of survival with no evidence of progression of the disease.

Trial Locations

Locations (1)

Army Medical Center of the People's Liberation Army

🇨🇳

Chongqing, Chongqing, China

© Copyright 2025. All Rights Reserved by MedPath